Mood Disorders

AMA to Collect Data on Suicide Among Doctors-in-Training

November 15, 2018

"While we have been working hard to reduce burnout and increase access to mental health services for physicians and medical students, it is imperative that we also work toward fully understanding the problem," said AMA Board Member, Ryan Ribeira MD.

Oral Therapy for Suicidal Bipolar Depression Gets Breakthrough Designation

By November 13, 2018

NRX-101 combines D-cycloserine (DCS), an N-methyl-D-aspartate (NMDA) receptor antagonist, and lurasidone, a D2/5-HT2a receptor antagonist.

Buprenorphine/Samidorphan Helpful in Refractory Depression

November 06, 2018

In pooled analyses of the 2 studies, consistently greater reduction was seen in MADRS scores from baseline for BUP/SAM 2mg/2mg versus placebo at multiple time points, including EOT and average change from baseline to week three through EOT.

FDA Panel Votes on Postpartum Depression Treatment Zulresso

By November 06, 2018

If approved, Zulresso would be the first drug approve for the treatment of postpartum depression.

FDA Committees Vote on Opioid System Modulator for MDD Treatment

By November 05, 2018

In the meeting documents, the panel presented a scenario which illustrated their concerns regarding potentially complex drug interactions that may occur in the population for which the drug is intended.

More Children Visiting Pediatric EDs for Mental Health

November 02, 2018

Over time, there was an increase in the rates of mental health visits, from 50.4 to 78.5 per 100,000 children in 2012 and 2016, respectively.

New Blood Test Identifies Metabolic Subtypes Linked to Autism Spectrum Disorder

By November 02, 2018

The NPDX AA test works by detecting amine imbalances in a child's fasting blood sample with very precise thresholds that were identified and validated based on samples from the Children's Autism Metabolome Project (CAMP) study (N=1100) in patients aged 18 to 48 months

Diagnoses, Treatment of Mental Health Conditions Up in College

October 31, 2018

The highest odds ratios were seen for anxiety, panic attacks, and attention deficit hyperactivity disorder (odds ratios, 1.68, 1.61, and 1.4, respectively).

Neither Haloperidol, Ziprasidone Shortens Delirium in ICU

October 26, 2018

The researchers found that patients were exposed to a trial drug or placebo for a median duration of four days. The median number of days alive without delirium or coma was 8.5, 7.9, and 8.7 in the placebo, haloperidol, and ziprasidone groups (P=0.26 for overall effect across trial groups).

Psilocybin Gets Breakthrough Tx Designation for Treatment-Resistant Depression

By October 24, 2018

The designation was granted to COMPASS Pathways, a life sciences company investigating psilocybin in a Phase 2b trial involving 216 patients at multiple sites across Europe and North America.

Vortioxetine Beats Escitalopram in Improving SSRI-Induced Sexual Dysfunction

By October 22, 2018

In the 8-week, randomized, double-blind study, patients with depression who had TESD (N=447) while taking an SSRI (eg, paroxetine, sertraline or citalopram) were switched to Trintellix or escitalopram, due to SSRI-induced sexual dysfunction.

Mortality Due to Suicide, Alcohol, Accidents Up in Diabetes

October 19, 2018

Among the 434,629 individuals included in the researcher, there were 2832 deaths due to alcohol, 3187 deaths due to accidents, and 853 deaths due to suicide during a mean follow-up of 7.1 years.

Dose Range of IV Ketamine for Adjunct Tx of Depression Tested

October 17, 2018

Compared with the active placebo, the infusions of ketamine were relatively well tolerated, except for greater dissociative symptoms and transient blood pressure elevations with the higher doses.

Sexual Harassment, Assault Tied to Women's Health Issues

October 05, 2018

Among women not taking antihypertensives, sexual harassment was correlated with significantly increased odds of stage 1 or 2 hypertension (odds ratio, 2.36) as well as clinically poor sleep (odds ratio, 1.89) after adjustment for covariates.

Abuse of Antidepressant for Weight Loss Leads to Seizures in Patient With Bulimia Nervosa

By October 03, 2018

The patient obtained prescriptions for bupropion XR from psychiatrists and primary care physicians who were not aware of her past medical history.

High HbA1c After T1DM Diagnosis Predicts Psychiatric Comorbidity

October 03, 2018

Higher risk for psychiatric diagnoses was predicted by high average HbA1c levels during the first 2 years of diabetes onset.

Global Cognition Up for Youth Meeting Movement Guidelines

October 02, 2018

The researchers found that the mean number of guidelines met was 1.1; 51, 37, and 18% of participants met the daily recommendations for sleep time (9 to 11 hours/night), screen time (2 hours or less), and physical activity (60 minutes or more), respectively.

NDA Submitted for Novel Schizophrenia Treatment Lumateperone

By September 28, 2018

Lumateperone, a first-in-class molecule, works via potent interactions at 5-HT2A receptors, serotonin transporters, and D1 receptors with indirect glutamatergic modulation.

Researchers Recommend Reclassification of Psilocybin

By September 27, 2018

Currently, psilocybin, a serotonin receptor agonist, is classified as a Schedule I agent as it has not been approved by the Food and Drug Administration (FDA) for any therapeutic use.

FDA to Review Vraylar sNDA for Treatment of Bipolar Depression

By September 26, 2018

The sNDA included findings from the RGH-MD-53, RGH-MD-54, and RGH-MD-56 trials in which cariprazine was associated with greater improvement in change from baseline to week 6 on the Montgomery Asberg Depression Rating scale (MADRS) total score vs placebo in bipolar I patients.

Psychiatric Adverse Effects of Disease-Modifying Therapies Assessed in MS Patients

By September 25, 2018

The primary outcome measure of the study was the frequency of any adverse psychiatric effect observed during treatment with one of these agents.

High-Risk Anticholinergics Prescribed to Six Percent of Elderly

September 25, 2018

The researchers found that a high-risk anticholinergic prescription was listed for 6.2% of visits of older adults between 2006 and 2015, representative of 14.6 million total visits nationally.

Physician Burnout Rates Vary by Medical Specialty

September 11, 2018

Nearly half of those in critical care, neurology, family medicine, ob-gyn, internal medicine report burnout

Treating Older Adult Bipolar Disorder: Newer Atypical Antipsychotics Compared

By September 10, 2018

While pharmacologic agents such as lithium and valproic acid have been shown to provide significant antimanic effects in older adults with bipolar disorder, an increase in the use of atypical antipsychotics in the general adult bipolar population prompted researchers to investigate the efficacy and tolerability of these agents in OABD.

Guidelines for Managing Perimenopausal Depression Now Available

By September 05, 2018

The 5 topics addressed by the 11-member expert panel include epidemiology, clinical presentation, therapeutic effects of antidepressants, effects of hormone therapy, and the effectiveness of other therapies (eg, psychotherapy, exercise, natural health products).

Esketamine Nasal Spray NDA Submitted to FDA for Treatment-Resistant Depression

By September 04, 2018

The NDA includes five Phase 3 studies in patients with treatment-resistant depression: 3 short-term studies, 1 withdrawal maintenance of effect study, and 1 long-term safety study.

Self-Injury Tops Diabetes As Cause of Death in United States

September 04, 2018

The researchers found that in 2015, SIM surpassed diabetes as a cause of death in the United States. In 2016, the gap expanded, with rates of 29.1 and 24.8 per 100,000 population, respectively.

Remission of Schizophrenia Seen With Amisulpride, Clozapine

September 04, 2018

Overall, 45 and 44% on amisulpride and olanzapine, respectively, achieved remission (P=.87). Twenty-eight of the 40 patients not in remission started clozapine; 28% of the 18 patients who completed treatment achieved remission.

Risk of Depression Up in Autism Spectrum Disorder

September 04, 2018

The researchers found that by age 27 years, 19.8% of individuals diagnosed with ASD had a diagnosis of depression, compared with 6.0% among the general population (adjusted relative risk [RR], 3.64).

Psilocybin Study Gets Green Light From FDA for Treatment-Resistant Depression

By August 22, 2018

The trial will be a Phase 2b dose-ranging study (N=216) with patients from 12-15 research centers across Europe and North America.